Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study

International Journal of Immunopathology and Pharmacology

Volumn 28, Issue 4, 2015, Pages 479-487

  Lorenzin, Mariagrazia ^a   Ortolan, Augusta ^a   De Hooge, Manouk ^a   Frallonardo, Paola ^a   Piccoli, Antonio ^a   Cozzi, Franco ^a   Oliviero, Francesca ^a   Punzi, Leonardo ^a   Ramonda, Roberta ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

adalimumab; anti TNF agents; etanercept; minimal disease activity; psoriatic arthritis; spondyloarthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; BIOLOGICAL THERAPY; CHRONOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; TIME FACTOR;

ADALIMUMAB; ADULT; AGED; ARTHRITIS, PSORIATIC; ETANERCEPT; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84946100151     PISSN: 03946320     EISSN: 20587384     Source Type: Journal    
DOI: 10.1177/0394632015599446     Document Type: Article

References (31)

1. Moll JM, Wright V, (1973) Psoriatic arthritis. Seminars in Arthritis and Rheumatism 3: 55-78.
2. Ramonda R, Lo Nigro A, Modesti V, et al. (2011) Atherosclerosis in psoriatic arthritis. Autoimmunity Reviews 10: 773-778.
3. Puato M, Ramonda R, Doria A, et al. (2014) Impact of hypertension on vascular remodelling in patients with psoriatic arthritis. Journal of Human Hypertension 28: 105-110.
4. Rodgers M, Epstein D, Bojke L, et al. (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: A systematic review and economic evaluation. Health Technology Assessment 15: 1-329.
5. Ramonda R, Modesti V, Ortolan A, et al. (2013) Serological markers in psoriatic arthritis: Promising tools. Experimental Biology and Medicine 238: 1431-1436.
6. Ramonda R, Puato M, Punzi L, et al. (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers. A two-year prospective observational study. Joint Bone Spine 81: 421-425.
7. Mease PJ, Gladman DD, Ritchlin CT, et al. (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 52: 3279-3289.
8. Mease PJ, Kivitz AJ, Burch FX, et al. (2004) Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis and Rheumatism 50: 2264-2272.
9. Gladman DD, Mease PJ, Ritchlin CT, et al. (2007) Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis and Rheumatism 56: 476-488.
10. Mease PJ, Kivitz AJ, Burch FX, et al. (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. Journal of Rheumatology 33: 712-721.
11. Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, et al. (2013) Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. Journal of Clinical Pharmacy and Therapeutics 38: 286-293.
12. Ash Z, Gaujoux-Viala C, Gossec L, et al. (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases 71: 319-326.
13. Gladman DD, Tom BD, Mease PJ, et al. (2010) Informing response criteria for psoriatic arthritis. I. Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. Journal of Rheumatology 37: 1892-1897.
14. Modesti V, Ramonda R, Ortolan A, et al. (2012) Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scandinavian Journal of Rheumatology 41: 490-491.
15. Coates LC, Fransen J, Helliwell PS, (2010) Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Annals of the Rheumatic Diseases 69: 48-53.
16. Inciarte-Mundo J, Hernández MV, Rosario V, et al. (2014) Reduction of biological agent dose in rheumatic diseases: Descriptive analysis of 153 patients in clinical practice conditions. Reumatologia Clinica 10: 10-16.
17. Gibson J, Harris H, McLaren S, (2012) Reduced dose and frequency of anti-TNF therapy in rheumatic diseases. Annals of the Rheumatic Diseases 71: 103.
18. Costa L, Caso F, Ramonda R, et al. (2014) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: An observational study. Immunologic Research 61: 147-153.
19. Smolen JS, Landewé R, Breedveld FC, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti rheumatic drugs. Annals of the Rheumatic Diseases 69: 964-975.
20. Ometto F, Botsios C, Raffeiner B, et al. (2010) Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmunity Reviews 9: 161-164.
21. den Broeder AA, van Herwaarden N, van der Maas A, et al. (2013) Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disorders 14: 299.
22. Cantini F, Niccoli L, Cassará E, et al. (2012) Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study. Biologics 6: 201-206.
23. López-Vives L, Estrada PV, Martín-Esteve I, (2012). Dose reduction and/or withdrawal of anti-TNF treatment in psoriatic arthritis. Annals of the Rheumatic Diseases 71: 133.
24. Taylor W, Gladman D, Helliwell P, et al.; CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis and Rheumatism 54: 2665-2673.
25. Mease PJ, (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Func-tional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care & Research 63: S64-85.
26. Saad AA, Symmons DP, Noyce PR, et al. (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials. Journal of Rheumatology 35: 883-890.
27. Saad AA, Ashcroft DM, Watson KD, et al.; BSRBR (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: An observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 49: 697-705.
28. Costa L, Caso F, Atteno M, et al. (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology 33: 833-839.
29. Chimenti MS, Esposito M, Giunta A, et al. (2013) Remission of psoriatic arthritis after etanercept discontinuation: Analysis of patients' clinical characteristics leading to disease relapse. International Journal of Immunopathology and Pharmacology 26: 833-838.
30. Raffeiner B, Botsios C, Ometto F, et al. (2015) Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology 33: 63-68.
31. Wada T, Son Y, Ozaki Y, et al. (2012) Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis. Modern Rheumatology 22: 824-830.